We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study. (MFM-Play pilot)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04435093
Recruitment Status : Completed
First Posted : June 17, 2020
Last Update Posted : May 28, 2021
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

The Motor Function Measure (MFM) is a functional rating scale consisting of 32 items assessing motor functional abilities in a person with neuromuscular disease.

By exploring the potential of digital technologies applied to MFM, for each item completion we want to create digital animations containing different playful and informative scenarios. This digital evolution aims to standardize assessment on the therapist's side, but also to improve acceptance of scale and patient participation.

Despite the modification of the MFM completion by digital animation, the study hypothesis is that the metrological qualities of the scale are retained.

Through the MFM-Play pilot study, the objective is to test 5 items of the MFM-Play scale before carrying out a validation study of the total MFM-Play.

Condition or disease Intervention/treatment
Neuromuscular Diseases Other: MFM-Play

Layout table for study information
Study Type : Observational
Actual Enrollment : 19 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study.
Actual Study Start Date : September 21, 2020
Actual Primary Completion Date : March 4, 2021
Actual Study Completion Date : March 4, 2021

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
MFM completion Other: MFM-Play
Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.

Primary Outcome Measures :
  1. MFM scores item 18 to 22 [ Time Frame: Day 1 ]
    Level of agreement between the scores obtained during the classic mode and during the MFM-Play mode, completed by two different therapists.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study will involve children with a neuromuscular disease, aged 6 to 11 years old

Inclusion Criteria:

  • Girls and boys with a neuromuscular disease
  • Aged 6 to 11 years old
  • With parental assent

Exclusion Criteria:

  • Patients participating to a therapeutic trial
  • Patients without compartmental capacities to participate normally to the MFM.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04435093

Layout table for location information
Hospices Civils de Lyon
Bron, France, 69500
CHU de Grenoble
La Tronche, France, 38700
CHU Saint Etienne
Saint-Étienne, France, 42055
Sponsors and Collaborators
Hospices Civils de Lyon
Layout table for investigator information
Principal Investigator: Dominique Vincent-Genod Hospices Civils de Lyon
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT04435093    
Other Study ID Numbers: 69HCL20_0150
2020-A01752-37 ( Other Identifier: ID-RCB )
First Posted: June 17, 2020    Key Record Dates
Last Update Posted: May 28, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hospices Civils de Lyon:
Neuromuscular Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromuscular Diseases
Nervous System Diseases